ABSTRACT
OBJECTIVE:To observe the efficacy and safety of Shenqi jiangtang granule in the adjuvant treatment of type 2 dia-betes knee arthritis. METHODS:62 patients with type 2 diabetes knee arthritis were randomly divided into control group(31 cas-es) and observation group (31 cases). Control group received hypoglycemic and basic treatment for arthritis,including diet con-trol,exercise therapy and health education,as well as 0.25 g Metformin hydrochloride tablet with a meal,3 times a day + 50 mg Acarbose tablet with a meal,3 times a day,chewing;patients with arthritis pain 100 mg Aspirin enteric-coated tablet after a meal, once a day (chewing or breaking apart was prohibited). Observation group additionally received 3 g Shenqi jiangtang granule half an hour before a meal with 50 ml warm water,3 times a day. The treatment course for both groups was 6 months. Clinical effica-cy,and fasting plasma glucose(FPG),2 h postprandial blood glucose(2 h PG),glycated hemoglobin(HbA1c),interleukin-1β(IL-1β),IL-6 before and after treatment,and the incidence of adverse reactions in 2 groups were observed. RESULTS:The total effective rate in observation group was significantly higher than control group,the difference was statistically significant(P0.05). After treatment,FPG,2 h PG,HbA1c,IL-1β and IL-6 in 2 groups were significantly lower than before,and observation group was lower than control group,the differences were statistically significant(P0.05). CONCLUSIONS:Based on conventional treatment,Shenqi jiangtang granule shows obvious efficacy in the adjuvant treatment of type 2 diabetes knee arthritis.,it can reduce blood glucose and inflammation cy-tokine levels,mild symptoms of adverse reactions.
ABSTRACT
Objective To observe the effect of Shenqi Jiangtang granule (SJG) on atherosclerotic disease (LEAD) of lower extremity in patients with early type 2 diabetes mellitus (T2DM). Methods The patients were randomly assigned to a control group and a treatment group. 30 patients in the treatment group were treated by SJG and 30 patients in the control group were given Cilostazo. Both groups were treated for 3 months. Lower extremity vascular color Doppler image, blood levels of interleukin-6 (IL-6) were measured before and after the treatment. Results The thickness of atherosclerosis (AS) plaque and arterial media were obviously reduced (t=3.376, 3.468, P<0.05) , serum levels of IL-6 were also be lowered obviously (t=3.345, P<0.05) in the treatment group. While these indexes remained unchanged in the control group. Conclusion SJG has remarkable action in reducing the thickness of AS plaque and media of artery. The mechanism might be related with its reducing serum IL-6 level.